Evommune, Inc. raised $115 million in a Series C led by RA Capital Management and Sectoral Asset Management to support the clinical development of its EVO756 and EVO301 programs.
Evommune, Inc. raised $115 million in a Series C led by RA Capital Management and Sectoral Asset Management to support the clinical development of its EVO756 and EVO301 programs.
10/31/24, 12:35 PM
Location
palo altoMoney raised
$115 million
Industry
biotechnology
health care
Round Type
series c
Investors
Verition Fund Management, Symbiosis, Amplitude Ventures, Andera Partners, Eqt Life Sciences, Pivotal Bio Venture Partners, Allostery Investments Lp, Fem Health Ventures, Beiersdorf Venture Capital, Next Bio Capital, Adar1 Capital Management, Rtw Investments, Longwood Fund, Avego Bioscience Capital, Marshall Wace, B Capital, Sectoral Asset Management, Ra Capital Management
Evommune, Inc. has completed a $115 million Series C financing to advance its clinical-stage pipeline for chronic inflammatory diseases. The funding, co-led by RA Capital Management and Sectoral Asset Management, will facilitate clinical development and data readouts expected in the coming years.
Company Info
Location
palo alto, california, united states
Additional Info
Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is creating game-changing science with the goal of delivering therapies that address symptoms and halt progressive disease.